

A. Within−drug comparison only (between−drug ranking not performed)
Centring removes drug−level offsets; Spearman rho = 0.644, n = 548 curves (>=3 curves per drug)
Mean viability on common interval (centred within drug)
0.4
0.0
−0.4
−2
0
2
log10(fitted IC50 / max dose), centred within drug
Measured 50% crossing
Model−only, in range
Fitted IC50 > max dose
Fitted IC50 < min dose
B. Three drugs with most curves: same−interval AUC, ranked within drug
Ranks compare curves of the same drug; repeated cell labels can be distinct experiments
AUY922
common 0.001−0.256 uM, n=9
786−0 (rank 1/9)
639−V (rank 2/9)
769−P (rank 3/9)
697 (rank 4/9)
5637 (rank 5/9)
8−MG−BA (rank 6/9)
22RV1 (rank 7/9)
647−V (rank 8/9)
23132−87 (rank 9/9)
AZD6482
common 0.02−5 uM, n=10
639−V (rank 1/10)
786−0 (rank 2/10)
23132−87 (rank 3/10)
8−MG−BA (rank 4/10)
697 (rank 5/10)
697 (rank 6/10)
23132−87 (rank 7/10)
786−0 (rank 8/10)
639−V (rank 9/10)
8−MG−BA (rank 10/10)
AZD7762
common 0.00781−2 uM, n=9
647−V (rank 8/9)
697 (rank 1/9)
786−0 (rank 2/9)
639−V (rank 3/9)
23132−87 (rank 4/9)
8−MG−BA (rank 5/9)
5637 (rank 6/9)
769−P (rank 7/9)
22RV1 (rank 9/9)
0.00
0.25
0.50
0.75
1.00
Mean viability over the drug's common dose range (lower = more sensitive)